ARMO ARMO BioSciences Inc

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of ARMO BioSciences, Inc. (ARMO) on Behalf of Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--

Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. (NASDAQ: ARMO) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY).

Our investigation concerns whether ARMO’s board of directors failed to adequately shop the Company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Eli Lilly. Under the terms of the agreement, ARMO stockholders will receive $50.00 per share in cash for each ARMO share that they own.

If you own ARMO shares, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at [email protected], or telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation of ARMO BioSciences, Inc., please go to http://www.bespc.com/ARMO. For additional information about Bragar Eagel & Squire, P.C., please go to www.bespc.com.

EN
10/05/2018

Underlying

ARMOARMO BioSciences Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ARMO BioSciences Inc

 PRESS RELEASE
Free
ARMO ARMO BioScience...

Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of...

NEW YORK--(BUSINESS WIRE)-- Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of ARMO BioSciences, Inc. (NASDAQ: ARMO) stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Our investigation concerns whether ARMO’s board of directors failed to adequately shop the Company and obtain the best possible value for its stockholders before entering into a definitive merger agreement with Eli Lilly. Under the terms of the agreement, ARMO stockholders will receive $...

May 10, 2018 1 EN
 PRESS RELEASE
Free
ARMO ARMO BioScience...

ARMO BIOSCIENCES, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Annou...

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of ARMO BioSciences, Inc. (NASDAQ GS: ARMO)? Did you purchase any of your shares prior to May 10, 2018? Do you think the proposed buyout is fair? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQ GS: ARMO) regar...

May 10, 2018 1 EN
 PRESS RELEASE
Free
ARMO ARMO BioScience...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Inve...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased ARMO BioSciences, Inc. (“ARMO” or the “Company”) (NASDAQGS: ARMO) stock prior to May 10, 2018. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of ARMO to Eli Lilly and Company (NYSE: LLY) for $50 per share. To learn more about the action and your rights, go to: http://www.zlk.com/mna/armo-biosciences-inc ...

May 10, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch